Laduviglusib, GMP Grade

• Cat.No.: Laduviglusib-05
• Product Overview: Laduviglusib (CHIR-99021) (GMP) is Laduviglusib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture.

Specification

• Description: Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.
• Form: Solid, White to off-white
• Target: GSK-3; Wnt; β-catenin; Autophagy
• In Vitro: Laduviglusib (GMP) (20 μM, 21 days) transdifferentiates mouse fibroblasts to neurons (determined by increased number of TAUEGFP-/TUJ1-positive neuronal cells). Laduviglusib (GMP) (3-5 μM, 2 days) induces somatic cells differentiation of pluripotent stem (PS) cells (the detailed method refers to the reference). Laduviglusib (GMP) (12 μM, 5 days) converts human fibroblasts (HFF) into functional cardiomyocytes. Laduviglusib (GMP) (3 μM, 4 days, hESCs) activates the canonical WNT signaling pathway, confirmed by β-catenin translocation into the nucleus. Laduviglusib (GMP) (in MEFs expressing MyoD) enhances the marked increase in the number of proliferative cells led by RepSox (GMP) together with Forskolin. Laduviglusib (GMP) (5 μM, 1 day) can be used to generate islets (hCiPSC-islets) from human chemically induced pluripotent stem cells (hCiPSC).
• IC50 & Target: GSK-3β: 6.7 nM (IC50) GSK-3α: 10 nM (IC50) CDC2: 8800 nM (IC50)
• CAS: 252917-06-9
• Formula: C22H18Cl2N8
• Molecular Mass: 465.34
• Shipping: Shipping with dry ice.

Gene Information

• Pathway: PI3K/Akt/mTOR; Stem Cell/Wnt; Autophagy
• Official Symbol: Laduviglusib
• Synonyms: Laduviglusib; CHIR-99021; CT99021